Nothing Special   »   [go: up one dir, main page]

HK1079981B - 含有阿巴卡韋和阿洛夫定的藥物製劑及其用途 - Google Patents

含有阿巴卡韋和阿洛夫定的藥物製劑及其用途

Info

Publication number
HK1079981B
HK1079981B HK06100011.9A HK06100011A HK1079981B HK 1079981 B HK1079981 B HK 1079981B HK 06100011 A HK06100011 A HK 06100011A HK 1079981 B HK1079981 B HK 1079981B
Authority
HK
Hong Kong
Prior art keywords
alovudine
abacavir
pharmaceutical preparation
pharmaceutical
treatment
Prior art date
Application number
HK06100011.9A
Other languages
English (en)
Other versions
HK1079981A1 (en
Inventor
Göran Mårdh
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202022A external-priority patent/SE0202022D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of HK1079981A1 publication Critical patent/HK1079981A1/xx
Publication of HK1079981B publication Critical patent/HK1079981B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
HK06100011.9A 2002-06-27 2006-01-03 含有阿巴卡韋和阿洛夫定的藥物製劑及其用途 HK1079981B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202022A SE0202022D0 (sv) 2002-06-27 2002-06-27 Synergistic interaction of abacavir and alovudine
EP02024744 2002-11-06
PCT/SE2003/001100 WO2004002433A1 (en) 2002-06-27 2003-06-24 Synergistic interaction of abacavir and alovudine

Publications (2)

Publication Number Publication Date
HK1079981A1 HK1079981A1 (en) 2006-04-21
HK1079981B true HK1079981B (zh) 2007-10-12

Family

ID=30001852

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100011.9A HK1079981B (zh) 2002-06-27 2006-01-03 含有阿巴卡韋和阿洛夫定的藥物製劑及其用途

Country Status (19)

Country Link
US (1) US20060084627A1 (zh)
EP (1) EP1536800B1 (zh)
JP (1) JP2005533870A (zh)
KR (1) KR20050013628A (zh)
CN (1) CN1302779C (zh)
AT (1) ATE314851T1 (zh)
AU (1) AU2003239088B2 (zh)
BR (1) BR0311141A (zh)
CA (1) CA2481890A1 (zh)
DE (1) DE60303131T2 (zh)
ES (1) ES2254941T3 (zh)
HK (1) HK1079981B (zh)
IL (1) IL164921A0 (zh)
MX (1) MXPA04012754A (zh)
NO (1) NO20050445L (zh)
NZ (1) NZ535817A (zh)
PL (1) PL373758A1 (zh)
RU (1) RU2320347C2 (zh)
WO (1) WO2004002433A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610797A1 (en) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of nevirapine and a further antiretroviral compound
GB0608876D0 (en) 2006-05-05 2006-06-14 Medivir Ab Combination therapy
KR101830715B1 (ko) 2010-01-27 2018-04-04 비이브 헬쓰케어 컴퍼니 Hiv 감염을 치료하기 위한 약학적 조합물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
CN1257912C (zh) * 1998-08-10 2006-05-31 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β－L－2′－脱氧－核苷
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
ATE324894T1 (de) * 1999-01-22 2006-06-15 Univ Emory Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5- fluorocytidin für die verwendung in der behandlung von hiv infektionen
US6514979B1 (en) * 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
CA2411354A1 (en) * 2000-06-02 2001-12-13 Smithkline Beecham Corporation Methods of treating viral diseases with il-18 and il-18 combinations

Also Published As

Publication number Publication date
ATE314851T1 (de) 2006-02-15
BR0311141A (pt) 2005-06-07
NO20050445L (no) 2005-01-26
PL373758A1 (en) 2005-09-05
EP1536800B1 (en) 2006-01-04
ES2254941T3 (es) 2006-06-16
WO2004002433A8 (en) 2004-05-06
EP1536800A1 (en) 2005-06-08
MXPA04012754A (es) 2005-03-23
NZ535817A (en) 2006-11-30
HK1079981A1 (en) 2006-04-21
US20060084627A1 (en) 2006-04-20
DE60303131D1 (de) 2006-03-30
AU2003239088B2 (en) 2006-11-02
CA2481890A1 (en) 2004-01-08
RU2320347C2 (ru) 2008-03-27
CN1665509A (zh) 2005-09-07
IL164921A0 (en) 2005-12-18
DE60303131T2 (de) 2006-07-20
CN1302779C (zh) 2007-03-07
JP2005533870A (ja) 2005-11-10
WO2004002433A1 (en) 2004-01-08
RU2005101874A (ru) 2005-06-27
AU2003239088A1 (en) 2004-01-19
KR20050013628A (ko) 2005-02-04

Similar Documents

Publication Publication Date Title
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
MXPA03007712A (es) Sales farmaceuticas.
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
HUP0401174A3 (en) Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds
CA2428160A1 (en) Compositions for antitumor treatment containing ecteinascidin 743
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
IL150528A0 (en) Ibuprofen containing active agent preparation
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
HK1068606A1 (en) Novel aminobenzoephenones
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
HK1079981A1 (en) A pharmaceutical preparation comprising a abacavirand alovudine and use thereof
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
AU2502301A (en) Medicament and combination of compatible medicaments
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.
IL162857A0 (en) Oral vaccination
MXPA01011964A (es) Forma de unidad de dosis farmaceutica del tipo de capsulas rigidas que contiene clonixinato de lisina, procedimiento para su preparacion y el uso de dicha unidad de dosis como analgesico y7o antiinflamatorio.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110624